{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,19]],"date-time":"2025-06-19T04:07:44Z","timestamp":1750306064284,"version":"3.41.0"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T00:00:00Z","timestamp":1748390400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100007065","name":"Universit\u00e0 degli Studi di Salerno","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007065","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology Reports"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.gore.2025.101776","type":"journal-article","created":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T23:19:43Z","timestamp":1748474383000},"page":"101776","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["BRAF V600E mutation associated with papillary high-grade serous ovarian cystadenocarcinoma in a 22q11.2DS patient"],"prefix":"10.1016","volume":"59","author":[{"given":"Maria Antonietta","family":"Castaldi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nadia","family":"Petrillo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmine","family":"Selleri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monica","family":"Ianniello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna Maria","family":"Della Corte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eloisa","family":"Evangelista","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luigia","family":"De Falco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Sirica","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marika","family":"Casillo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessia","family":"Caleo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro","family":"Caputo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pio","family":"Zeppa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salvatore Giovanni","family":"Castaldi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pasqualina","family":"Scala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bianca","family":"Serio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni","family":"Savarese","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valentina","family":"Giudice","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.gore.2025.101776_b0005","doi-asserted-by":"crossref","first-page":"E802","DOI":"10.9778\/cmajo.20200294","article-title":"Estimate of the contemporary live-birth prevalence of recurrent 22q11.2 deletions: a crosssectional analysis from population-based newborn screening","volume":"9","author":"Blagojevic","year":"2021","journal-title":"CMAJ Open"},{"issue":"9","key":"10.1016\/j.gore.2025.101776_b0010","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.cancergen.2014.05.007","article-title":"Malignant rhabdoid tumor of the bladder and ganglioglioma in a 14 year-old male with a germline 22q11.2 deletion","volume":"207","author":"Bosse","year":"2014","journal-title":"Cancer Genet."},{"issue":"4","key":"10.1016\/j.gore.2025.101776_b0015","first-page":"719","article-title":"Localization of an ovarian cancer tumor suppressor gene to a 0.5-cM region between D22S284 and CYP2D, on chromosome 22q","volume":"56","author":"Bryan","year":"1996","journal-title":"Cancer Res."},{"issue":"3","key":"10.1016\/j.gore.2025.101776_b0020","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1002\/ijc.28705","article-title":"Exome sequencing reveals frequent inactivating mutations in ARID1A, ARID1B, ARID2 and ARID4A in microsatellite unstable colorectal cancer","volume":"135","author":"Cajuso","year":"2014","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.gore.2025.101776_b0025","article-title":"BRAF mutations occur infrequently in ovarian cancer but suggest responsiveness to BRAF and MEK inhibition","volume":"2","author":"Campos","year":"2018","journal-title":"JCO Precis. Oncol."},{"issue":"26","key":"10.1016\/j.gore.2025.101776_b0030","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","article-title":"Improved survival with vemurafenib in melanoma with BRAF V600E mutation","volume":"364","author":"Chapman","year":"2011","journal-title":"N. Engl. J. Med."},{"issue":"206","key":"10.1016\/j.gore.2025.101776_b0035","article-title":"Systemic review on B-RafV600Emutation as potential therapeutic target for the treatment of cancer","volume":"15","author":"Chavda","year":"2020","journal-title":"Eur. J. Med. Chem."},{"issue":"5","key":"10.1016\/j.gore.2025.101776_b0040","doi-asserted-by":"crossref","DOI":"10.1200\/PO.21.00055","article-title":"Spectrum of BRAF mutations and gene rearrangements in ovarian serous carcinoma","volume":"16","author":"Chui","year":"2021","journal-title":"JCO Precis. Oncol."},{"issue":"1","key":"10.1016\/j.gore.2025.101776_b0045","doi-asserted-by":"crossref","first-page":"37","DOI":"10.3390\/s24010037","article-title":"Biomarkers in Cancer detection, diagnosis, and prognosis","volume":"24","author":"Das","year":"2023","journal-title":"Sensors (Basel)"},{"issue":"6892","key":"10.1016\/j.gore.2025.101776_b0050","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/nature00766","article-title":"Mutations of the BRAF gene in human cancer","volume":"417","author":"Davies","year":"2002","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.gore.2025.101776_b0055","doi-asserted-by":"crossref","first-page":"4057","DOI":"10.3390\/ijms24044057","article-title":"Expanding the spectrum of BRAF Non-V600E mutations in thyroid nodules: evidence-based data from a tertiary referral centre","volume":"24","author":"De Leo","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"7","key":"10.1016\/j.gore.2025.101776_b0060","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1097\/PAS.0b013e31802cbbe9","article-title":"The development of high-grade serous carcinoma from atypical proliferative (borderline) serous tumors and low-grade micropapillary serous carcinoma: a morphologic and molecular genetic analysis","volume":"31","author":"Dehari","year":"2007","journal-title":"Am. J. Surg. Pathol."},{"issue":"5","key":"10.1016\/j.gore.2025.101776_b0065","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1002\/ajmg.a.33957","article-title":"Wilms tumor in a patient with 22q11.2 microdeletion","volume":"155A","author":"Finch","year":"2011","journal-title":"Am. J. Med. Genet. A"},{"issue":"9","key":"10.1016\/j.gore.2025.101776_b0070","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa1002011","article-title":"Inhibition of mutated, activated BRAF in metastatic melanoma","volume":"363","author":"Flaherty","year":"2010","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.gore.2025.101776_b0075","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s10238-024-01313-3","article-title":"Non-invasive prenatal test identifies circulating cell-free DNA chromosomal abnormalities derived from clonal hematopoiesis in aggressive hematological malignancies","volume":"24","author":"Giudice","year":"2024","journal-title":"Clin. Exp. Med."},{"issue":"6","key":"10.1016\/j.gore.2025.101776_b0080","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1200\/JCO.2017.75.3780","article-title":"Targeted therapy for advanced solid tumors on the basis of molecular profiles: results from mypathway, an open-label, phase iia multiple basket study","volume":"36","author":"Hainsworth","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"12","key":"10.1016\/j.gore.2025.101776_b0085","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1016\/j.humpath.2010.03.014","article-title":"Epstein-Barr virus-positive T-cell lymphoma cells having chromosome 22q11.2 deletion: an autopsy report of DiGeorge syndrome","volume":"42","author":"Itoh","year":"2011","journal-title":"Hum. Pathol."},{"issue":"10","key":"10.1016\/j.gore.2025.101776_b0090","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1136\/ijgc-2024-005305","article-title":"Molecular changes driving low-grade serous ovarian cancer and implications for treatment","volume":"34","author":"Kelliher","year":"2024","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"1","key":"10.1016\/j.gore.2025.101776_b0095","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.path.2010.12.009","article-title":"Molecular pathology of ovarian carcinomas","volume":"4","author":"K\u00f6bel","year":"2011","journal-title":"Surg. Pathol. Clin."},{"issue":"10","key":"10.1016\/j.gore.2025.101776_b0100","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1002\/ajmg.a.38474","article-title":"The 22q11.2 deletion syndrome: Cancer predisposition, platelet abnormalities and cytopenias","volume":"176","author":"Lambert","year":"2018","journal-title":"Am. J. Med. Genet. A"},{"issue":"2","key":"10.1016\/j.gore.2025.101776_b0105","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s00439-023-02635-0","article-title":"The pivotal role of long non-coding RNAs as potential biomarkers and modulators of chemoresistance in ovarian cancer (OC)","volume":"143","author":"Malgundkar","year":"2024","journal-title":"Hum. Genet."},{"issue":"3","key":"10.1016\/j.gore.2025.101776_b0110","doi-asserted-by":"crossref","first-page":"577","DOI":"10.21037\/jgo.2019.01.10","article-title":"Concomitant KRAS and BRAF mutations in colorectal cancer","volume":"10","author":"Midthun","year":"2019","journal-title":"J Gastrointest Oncol."},{"issue":"25","key":"10.1016\/j.gore.2025.101776_b0115","doi-asserted-by":"crossref","first-page":"20785","DOI":"10.18632\/oncotarget.4750","article-title":"Similar but different: distinct roles for KRAS and BRAF oncogenes in colorectal cancer development and therapy resistance","volume":"6","author":"Morkel","year":"2015","journal-title":"Oncotarget"},{"issue":"3","key":"10.1016\/j.gore.2025.101776_b0120","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/s11060-010-0350-2","article-title":"Temporal lobe pleomorphic xanthoastrocytoma and acquired BRAF mutation in an adolescent with the constitutional 22q11.2 deletion syndrome","volume":"102","author":"Murray","year":"2011","journal-title":"J. Neurooncol"},{"issue":"8","key":"10.1016\/j.gore.2025.101776_b0125","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1097\/MPH.0b013e318168f072","article-title":"Hypocalcemia in a patient with osteosarcoma and 22q11.2 deletion syndrome","volume":"30","author":"Mussai","year":"2008","journal-title":"J. Pediatr. Hematol. Oncol."},{"issue":"12","key":"10.1016\/j.gore.2025.101776_b0130","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1038\/sj.bjc.6604783","article-title":"KRAS or BRAF mutation status is a useful predictor of sensitivity to MEK inhibition in ovarian cancer","volume":"99","author":"Nakayama","year":"2008","journal-title":"Br. J. Cancer"},{"issue":"23","key":"10.1016\/j.gore.2025.101776_b0135","doi-asserted-by":"crossref","first-page":"11752","DOI":"10.18632\/oncotarget.2555","article-title":"BRAF vs RAS oncogenes: are mutations of the same pathway equal? Differential signalling and therapeutic implications","volume":"5","author":"Oikonomou","year":"2014","journal-title":"Oncotarget."},{"issue":"9","key":"10.1016\/j.gore.2025.101776_b0140","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1016\/j.ajhg.2024.07.013","article-title":"Evidence-based recommendations for gene-specific ACMG\/AMP variant classification from the ClinGen ENIGMA BRCA1 and BRCA2 Variant Curation Expert Panel","volume":"111","author":"Parsons","year":"2024","journal-title":"Am. J. Hum. Genet."},{"issue":"7","key":"10.1016\/j.gore.2025.101776_b0145","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.3390\/cancers12071823","article-title":"BRAF inhibitors: molecular targeting and immunomodulatory actions","volume":"12","author":"Proietti","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"7","key":"10.1016\/j.gore.2025.101776_b0150","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1097\/IGC.0000000000001041","article-title":"European society of gynaecological oncology (ESGO) guidelines for ovarian cancer surgery","volume":"27","author":"Querleu","year":"2017","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"2","key":"10.1016\/j.gore.2025.101776_b0155","first-page":"1209","article-title":"Identification of long non\u2013coding RNA expression patterns useful for molecular\u2013based classification of typeI endometrial cancers","volume":"41","author":"Ravo","year":"2019","journal-title":"Oncol. Rep."},{"issue":"11","key":"10.1016\/j.gore.2025.101776_b0160","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2014-005041","article-title":"Case fatality rate and associated factors in patients with 22q11 microdeletion syndrome: a retrospective cohort study","volume":"4","author":"Repetto","year":"2014","journal-title":"BMJ Open"},{"issue":"8","key":"10.1016\/j.gore.2025.101776_b0165","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0103884","article-title":"Decreased DGCR8 expression and miRNA dysregulation in individuals with 22q11.2 deletion syndrome","volume":"9","author":"Sellier","year":"2014","journal-title":"PLoS One"},{"issue":"12","key":"10.1016\/j.gore.2025.101776_b0170","doi-asserted-by":"crossref","first-page":"3586","DOI":"10.3390\/cells10123586","article-title":"Somatic mutational profile of high-grade serous ovarian carcinoma and triple-negative breast carcinoma in young and elderly patients: similarities and divergences","volume":"10","author":"Serio","year":"2021","journal-title":"Cells"},{"issue":"1","key":"10.1016\/j.gore.2025.101776_b0175","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.ajpath.2020.09.006","article-title":"The origin of ovarian cancer species and precancerous landscape","volume":"191","author":"Shih","year":"2021","journal-title":"Am. J. Pathol."},{"issue":"6","key":"10.1016\/j.gore.2025.101776_b0180","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1038\/s41379-021-00995-4","article-title":"Infiltration pattern predicts metastasis and progression better than the T-stage and grade in pancreatic neuroendocrine tumors: a proposal for a novel infiltration-based morphologic grading","volume":"35","author":"Taskin","year":"2022","journal-title":"Mod. Pathol."},{"issue":"10","key":"10.1016\/j.gore.2025.101776_b0185","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.1038\/s41436-019-0509-y","article-title":"All-cause mortality and survival in adults with 22q11.2 deletion syndrome","volume":"21","author":"Van","year":"2019","journal-title":"Genet. Med."},{"issue":"5","key":"10.1016\/j.gore.2025.101776_b0190","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1097\/PAP.0b013e3181b4fffa","article-title":"Ovarian low-grade and high-grade serous carcinoma: pathogenesis, clinicopathologic and molecular biologic features, and diagnostic problems","volume":"16","author":"Vang","year":"2009","journal-title":"Adv. Anat. Pathol."},{"issue":"5","key":"10.1016\/j.gore.2025.101776_b0195","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1038\/s41571-024-00881-3","article-title":"Global epidemiology of epithelial ovarian cancer","volume":"21","author":"Webb","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.gore.2025.101776_b0200","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2021.111889","article-title":"LncRNA DiGeorge syndrome critical region gene 5: a crucial regulator in malignant tumors","volume":"141","author":"Xia","year":"2021","journal-title":"Biomed. Pharmacother."}],"container-title":["Gynecologic Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352578925001018?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352578925001018?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T03:06:22Z","timestamp":1750215982000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352578925001018"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":40,"alternative-id":["S2352578925001018"],"URL":"https:\/\/doi.org\/10.1016\/j.gore.2025.101776","relation":{},"ISSN":["2352-5789"],"issn-type":[{"type":"print","value":"2352-5789"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"BRAF V600E mutation associated with papillary high-grade serous ovarian cystadenocarcinoma in a 22q11.2DS patient","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gore.2025.101776","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"101776"}}